Are you ready? November is #LungCancerAwarenessMonth . I’ll be tweeting every day in support using these hashtags. Let’s light up social media! #LCAM #lcsm #diecancerdie #lungcancer

So sorry I can’t attend. I still haven’t been able to buy a computer.

Nice editorial The Lancet Oncology by Balazs Halmos 👉Tissue-agnostic RET inhibition: can you trust your target? Gil Morgan Petros Grivas Giannis Mountzios thelancet.com/journals/lanon…

⭐️ #Sundaymorning read The Lancet Oncology 👉 The recently FDA approved Tumor-Agnostic Efficacy+ Safety of Selpercatinib in patients with RET+ solid tumors-LIBRETTO-001-🎯 data is published in the Oct 22 issue w a nice editorial OncoAlert #precisionmedicine bit.ly/3VueYzk

I think every org and company that has benefited from Melissa’s survival & story should donate to help her. Melissa Crouse lost everything in #HurricanIan
gofund.me/71ca1745
#lcsm #lungcancer

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer - ASCO Journals - goo.gl/alerts/6HgyDD #GoogleAlerts

Tissue-agnostic RET inhibition: can you trust your target? - The Lancet Oncology - goo.gl/alerts/JoFQrr #GoogleAlerts

PLEASE RT: I need help from the #lcsm community

Aetna, pls approve my onc’s 2nd appeal for #selumetinib for the TRIM 24 BRAF fusion that is driving my #lungcancer progression. I have received 2 prior denials

What’s the use of #biomarker testing if I can’t get the drug I need🧵

Study investigates the efficacy and safety of selpercatinib in a diverse group of patients - goo.gl/alerts/5rty51 #GoogleAlerts

Novartis presents new RET inhibitors for lung adenocarcinoma | BioWorld - goo.gl/alerts/6kpVwa #GoogleAlerts

Tissue-agnostic RET inhibition: can you trust your target? - The Lancet Oncology - goo.gl/alerts/oYwuYU #GoogleAlerts

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive ... - goo.gl/alerts/FW4hVv #GoogleAlerts

Phase I/II LIBRETTO-001 trial: RET inhibitor achieves durable objective responses across ... - goo.gl/alerts/MT4PW9 #GoogleAlerts

Fast Five Quiz: Non–Small Cell Lung Cancer (NSCLC) and RET Mutation - goo.gl/alerts/ScgneX #GoogleAlerts #LCSM

Phase 2 study of lung cancer gene panel testing demonstrates cytological specimens accurate - goo.gl/alerts/dpc3rr #GoogleAlerts

Pralsetinib achieves tissue-agnostic benefits for patients with RET gene fusions - Newswise - goo.gl/alerts/sgX3GZ #GoogleAlerts

An integrative pan cancer analysis of RET aberrations and their potential clinical implications - goo.gl/alerts/nmjyyS #GoogleAlerts

Pralsetinib Achieves Tissue-Agnostic Benefits for Patients With RET Fusion–Positive Cancers - goo.gl/alerts/fCKtgT #GoogleAlerts

Inhibitor of RET Receptor Tyrosine Kinase Shows Promise Against Multiple Cancers - goo.gl/alerts/D5611r #GoogleAlerts